Attorneys General File Suit Over Misleading Cord Blood Claims
AUSTIN, TX & PHOENIX, AZ – In a significant move to protect vulnerable consumers, the attorneys general of Texas and Arizona have jointly filed a lawsuit against Cord Blood Registry (CBR), one of the largest private cord blood banks in the United States. The legal action, announced on October 24, 2023, contends that CBR has engaged in a pattern of deceptive advertising, preying on the anxieties and hopes of expectant parents by exaggerating the medical benefits and likelihood of using privately stored umbilical cord blood.
Texas Attorney General Ken Paxton and Arizona Attorney General Kris Mayes allege that CBR, a subsidiary of CooperSurgical, Inc., has marketed its cord blood and tissue banking services with misleading claims, implying a broad spectrum of guaranteed future treatments for severe medical conditions. The lawsuit seeks injunctive relief, civil penalties, and restitution for affected consumers, highlighting a critical concern within the rapidly growing but often misunderstood private cord blood banking industry.
The Heart of the Allegations: False Promises and Pressure Tactics
The core of the states' complaint revolves around CBR's marketing materials and sales pitches, which allegedly overstate the therapeutic potential of privately banked cord blood and tissue. According to court documents filed in both states, CBR's advertisements frequently use phrases such as “biological insurance policy” and suggest that storing cord blood provides a comprehensive safeguard against a wide array of future diseases, including conditions like autism, cerebral palsy, and diabetes.
However, medical experts and regulatory bodies, including the American Academy of Pediatrics (AAP) and the American Medical Association (AMA), caution that the established uses for cord blood are currently limited to a specific range of hematopoietic stem cell transplants for certain cancers and blood disorders. While research into new applications is ongoing, many of the conditions touted by private banks remain largely experimental and are far from routine clinical application.
“New parents are often overwhelmed and highly susceptible to promises of protecting their child’s future health,” stated Attorney General Paxton in a press release. “CBR exploited this vulnerability, pushing expensive services with little basis in current medical fact. This is an unacceptable practice that demands accountability.”
The lawsuit details how CBR allegedly failed to adequately disclose the low probability that an individual child will ever actually use their own privately stored cord blood. Estimates from medical organizations suggest the likelihood is extremely low, often cited as less than 1 in 2,700 to 1 in 20,000, depending on the source. Despite this, parents are encouraged to pay initial collection fees, typically ranging from $1,500 to $2,500, followed by annual storage fees of $175 to $200, accumulating substantial costs over decades.
Navigating the Complexities of Cord Blood Banking
Cord blood, rich in hematopoietic stem cells, is collected from the umbilical cord after birth. These cells have the unique ability to develop into various types of blood cells and have been successfully used in transplants to treat over 80 diseases, primarily blood cancers and genetic disorders. However, the vast majority of these established uses involve cells from a donor (allogeneic transplant), often from public banks, rather than the child's own cells (autologous transplant).
The distinction between public and private banking is crucial. Public cord blood banks accept donations for altruistic use by anyone who is a match, similar to blood donation. Private banks, like CBR, store cord blood exclusively for the family's potential future use, for a fee. While private banking holds promise for future autologous therapies, the current medical consensus is that such uses are rare, and the long-term viability and efficacy of privately stored cells for many experimental treatments are still under investigation.
“Our investigation revealed that CBR created a false sense of urgency and necessity,” said Attorney General Mayes. “Parents were led to believe they were making a critical, time-sensitive decision to secure their child’s health, when in reality, they were often signing up for an expensive service with highly speculative benefits.”
Industry Scrutiny and Consumer Protection
The lawsuit against CBR is not an isolated incident; the private cord blood banking industry has faced scrutiny for years regarding its marketing practices. Critics argue that the industry profits from parental fear and a lack of comprehensive understanding of stem cell science.
The attorneys general are seeking:
- A permanent injunction to prevent CBR from continuing its deceptive marketing practices.
- Civil penalties for violations of state consumer protection laws (e.g., the Texas Deceptive Trade Practices Act and the Arizona Consumer Fraud Act).
- Restitution for consumers who were misled and paid for services under false pretenses.
- Reimbursement of attorney’s fees and investigative costs.
This legal challenge underscores the importance of transparency and ethical marketing in healthcare services, especially those targeting expectant parents. As the case proceeds, it is expected to send a strong message to the private cord blood banking industry about the need for accuracy and honesty in their communications with consumers.
